Abatacept for heart muscle inflammation caused by cancer immunotherapy
Tests abatacept against placebo in hospitalized people with myocarditis from cancer immunotherapy.
Key facts
- Who runs it
- Massachusetts General Hospital
- Where
- Ann Arbor, Baltimore, Bethlehem, Boston, Chapel Hill, Chicago, Cleveland, Dallas, Houston, Indianapolis, Kansas City, Lexington, Los Angeles, Milwaukee, Morgantown, New Brunswick, New York, Philadelphia, Pittsburgh, Portland, Rochester, Salt Lake City, Tampa, and Washington D.C., United StatesSee the 29 sitesAlso in 1 other country, 2 sites
- Trial code
- Registry title
- Abatacept in Immune Checkpoint Inhibitor Myocarditis
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 390 people, planned
- Started
- 2 Jul 2022
- Expected to end
- 9 Oct 2029
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Abatacept plus
- Placebo
- Record updated
- 20 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults in hospital with heart muscle inflammation (myocarditis) caused by cancer immune checkpoint inhibitor drugs. It tests abatacept against a placebo.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- A diagnosis of myocarditis while in hospital, with ongoing heart muscle damage.
- Earlier treatment
- An FDA-approved immune checkpoint inhibitor within 6 months of the myocarditis diagnosis. People must be on, or about to start within 24 hours, 1000 mg of solumedrol per day. No abatacept or belatacept in the last 2 months. No mycophenolate, JAK STAT inhibitors, tacrolimus, anti-thymocyte globulin, alemtuzumab, infliximab or plasma exchange in the last 2 months.
- Biomarker or test result
- Troponin at least 5 times the upper limit of normal within 10 days before joining. White blood cell count >2,500/μl, ANC >1,500/μL, and ALT or AST <20 times the upper limit of normal.
Main reasons for not taking part
- Sudden cardiac arrest, cardiogenic shock, or serious heart rhythm problems in the past 30 days
- Active hepatitis B or C, serious herpes infections, active Covid-19, or other serious viral infection
- Active or incompletely treated tuberculosis, or serious bacterial or fungal infection
- Pregnant, breastfeeding, or planning pregnancy
- Live vaccine in the 4 weeks before the first dose
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Must have provided informed consent in a manner approved by the Investigator's Institutional Review Board (IRB) prior to any study-related procedure being performed. If a participant is unable to provide informed consent due to his/her medical condition, the participant's legally authorized representative may consent on behalf of the study participant, as permitted by local law and institutional Standard Operating Procedures
- Aged greater than or equal to 18 years at the time of informed consent
- Recent use of an FDA-approved immune checkpoint inhibitor (ICI, defined as administered an immune checkpoint inhibitor ≤ 6 months of myocarditis diagnosis), alone or in combination with other cancer therapies (i.e. chemotherapy, radiation therapy or targeted therapy). The FDA-approved ICI could be given as part of a clinical trial but not in combination with a new investigational agent which may cause myocarditis
- A diagnosis of myocarditis
- Hospitalized at the time of randomization
- On 1000 mg of solumedrol per day for myocarditis or with an intent to initiate 1000 mg of solumedrol per day for myocarditis within 24 hours of first administration of study drug
- Serum evidence of ongoing myocardial injury: Serum evidence of ongoing myocardial injury will be defined as an institutional troponin (either conventional or high-sensitivity troponin I or T, using the standard institutional assay) with a value that is ≥5 times the upper limit of the reference standard normal for that institution. The troponin assay may be adjusted based on sex depending on institutional standards. This value of troponin of ≥5 times above the institutional upper limits of normal value must be noted within 10 days prior to potential randomization. The 10-day period can be in the outpatient or inpatient setting. For example, a participant with a troponin value that on one occasion was ≥5 times the upper limits of institutional normal in the 10-day window prior to potential randomization (whether in the inpatient or outpatient setting), but later decreases below that threshold, typically due to starting corticosteroids, would still be considered eligible
- The following laboratory parameters, not older than 48 hours at the time of randomization, and measured as part of usual care:; Total white blood cell (WBC) count >2,500/μl; Absolute neutrophil count (ANC) >1,500/μL; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) <20 times the upper limit of the institutional normal ranges
- Women of childbearing potential (i.e., not postmenopausal, or surgically sterilized) must have a negative highly sensitive urine or serum pregnancy test prior to randomization. Participating women of childbearing potential must be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug. Participating men must also be willing to consistently use effective methods of contraception from screening until at least 90 days after administration of the last dose of study drug; and
- Must be willing and able to abide by all study requirements and restrictions
Who cannot take part
- Must not have experienced any of the following (as defined in the section on the primary endpoint) in the 30-day period prior to randomization:; A sudden cardiac arrest; Cardiogenic shock as defined. A significant bradyarrhythmia (Mobitz type II second degree atrioventricular block or third degree (complete) atrio-ventricular (AV) block, for which an intervention with a temporary or permanent pacemaker is completed or recommended); A significant tachyarrhythmia (ventricular fibrillation of any duration or sustained ventricular tachycardia (>30 seconds, >120 beats per minute); or a ventricular tachyarrhythmia requiring intervention
- Concurrent or recent (≤2 month) use of the following non-corticosteroid immunosuppressive therapies prior to randomization: mycophenolate, JAK STAT inhibitors (including but not limited to upadacitinib, tofacitinib, baricitinib, and filgotinib), tacrolimus, anti-thymocyte globulin, alemtuzumab, infliximab, and plasma exchange. The use of intravenous immunoglobulin is permitted prior to randomization and during study treatment
- Female who is pregnant, breastfeeding, or is considering becoming pregnant during the study or for approximately 90 days after the last dose of study drug
- Male who is considering fathering a child or donating sperm during the study or for approximately 30 days after the last dose of study drug
- Receipt of any live vaccine within four weeks prior to the first dose of study drug, or expected need of live vaccination during study participation including at least 90 days after the last dose of IV study drug
- Any active, chronic, or recurrent viral infection that, based on the investigator's clinical assessment, makes the participant an unsuitable candidate for the study. These may include hepatitis B virus (HBV) or hepatitis C virus (HCV), recurrent or disseminated (even a single episode) herpes zoster, and disseminated (even a single episode) herpes simplex. Active HBV and HCV are defined as: HBV: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the HBV deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) qualitative test for Hepatitis B core antibody (HBc Ab) positive (+) participants; HCV: HCV ribonucleic acid (RNA) detectable in any participant with anti-HCV antibody (HCV Ab). Patients with active Covid-19 infection will be excluded. This is defined as the period of ongoing symptoms in the setting of a positive Covid-19 test, or until 10 days after symptom onset and after resolution of fever for at least 24 hours, without the use of fever-reducing medications
- Known active tuberculosis (TB), history of incompletely treated TB, suspected or known extrapulmonary TB, suspected or known systemic bacterial or fungal infections
- Any medical condition that could interfere with, or for which the treatment might interfere with, the conduct of the study or interpretation of the study results, or that would, in the opinion of the Investigator, increase the risk of the participant by participating in the study
- Any factors that, in the Investigator's opinion, are likely to interfere with study procedures, such as history of noncompliance with scheduled appointments
- Recent (≤2 month) exposure to abatacept or belatacept
- Currently enrolled in another interventional study utilizing systemic agents for the management of ICI-related toxicities
Where in United States
Also in 1 other country, 2 sites
- University of MichiganAnn Arbor, United StatesContact: Salim Hayek, MDTaking people
- Johns HopkinsBaltimore, United StatesContact: Joban VaishnavTaking people
- Lehigh Valley Health NetworkBethlehem, United StatesContact: Nicholas TraskTaking people
- Beth Israel Deaconess Medical CenterBoston, United StatesContact: Abul Aritizia, MDTaking people
- Boston Medical CenterBoston, United StatesContact: Omar SiddiqiTaking people
- Brigham and Women's HospitalBoston, United StatesContact: Anju Nohria, MDTaking people
- Massachusetts General HospitalBoston, United StatesContact: Daniel Zlotoff, MD, PhDTaking people
- University of North Carolina, Chapel HillChapel Hill, United StatesContact: Brian Jensen, MDTaking people
- University of ChicagoChicago, United StatesContact: Jeanne DeCaraTaking people
- Cleveland ClinicCleveland, United StatesContact: Rohit MoudgilTaking people
- University of Texas, SouthwesternDallas, United StatesContact: Saketh NadimpalliTaking people
- MD Anderson Cancer CenterHouston, United StatesContact: Nicolas PalaskasNot yet recruiting
- Franciscan HealthIndianapolis, United StatesContact: Ryan DalyTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Charles PorterTaking people
- University of KentuckyLexington, United StatesContact: Amit ArbuneTaking people
- Cedars-Sinai Medical CenterLos Angeles, United StatesContact: Kiranbir Josan, MDTaking people
- University of California, Los AngelesLos Angeles, United StatesContact: Eric Yang, MDTaking people
- Aurora St. Luke's Medical CenterMilwaukee, United StatesContact: Manmeet SinghTaking people
- University of West VirginiaMorgantown, United StatesContact: Brijesh PatelTaking people
- Robert Wood Johnson University HospitalNew Brunswick, United StatesContact: Amna ZafarTaking people
- Columbia University Irving Medical CenterNew York, United StatesContact: Jayant RaikhelkarTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesContact: Dipti Gupta, MDTaking people
- University of PennsylvaniaPhiladelphia, United StatesContact: Michael FradleyTaking people
- Allegheny-Singer Research InstitutionPittsburgh, United StatesContact: Valentyna IvanovaTaking people
- Maine HealthPortland, United StatesContact: Maxwell AfariTaking people
- Mayo ClinicRochester, United StatesContact: Joerg HerrmannTaking people
- University of UtahSalt Lake City, United StatesContact: Anees Daud, MDTaking people
- Moffitt Cancer CenterTampa, United StatesContact: Mohammed vTaking people
- MedStar Health Research Institute, Georgetown UniversityWashington D.C., United StatesContact: Hayder HashimTaking people
About the trial
What the trial wants to find out
The primary aim is to test whether abatacept, as compared to placebo, is associated with a reduction in major adverse cardiac events (MACE) among participants hospitalized with myocarditis secondary to an immune checkpoint inhibitor (ICI). The primary outcome, MACE, is a composite of first occurrence of cardiovascular death, non-fatal sudden cardiac arrest, cardiogenic shock, significant ventricular arrythmias, significant bradyarrythmias, or incident heart failure.
The 2 groups in the trial
- Abatacept plus standard of careTreatment being tested
Abatacept (10 mg/kg) will be administered IV after randomization, again at 24 hours after first study drug treatment, at 14 days after first study drug treatment and an optional 4th dose at 28 days.
Treatment: Abatacept plus
- Placebo plus standard of carePlacebo, for comparison
Placebo will be administered at the same intervals.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- AbatacepT foR ImmUne Checkpoint Inhibitor Associated Myocarditis (ATRIUM): A Phase 3, Investigator-Initiated, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in ICI Myocarditis
- Plain-language title
- Abatacept for heart muscle inflammation caused by cancer immunotherapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Publications
- Clinical Characteristics and Mechanisms of Acute Myocarditis.Circulation research, 2024
- Record updated
- 20 August 2026